Risk and prognosis of endometrial cancer after tamoxifen for breast cancer
Top Cited Papers
- 1 September 2000
- journal article
- research article
- Published by Elsevier in The Lancet
- Vol. 356 (9233) , 881-887
- https://doi.org/10.1016/s0140-6736(00)02677-5
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- IV.2 Does risk of endometrial cancer increase with longer duration of tamoxifen use?European Journal Of Cancer, 1998
- II.6 Alterations in steroid hormone receptors in the tamoxifen-treated endometriumEuropean Journal Of Cancer, 1998
- IV.6 Tamoxifen and endometrial cancer: most cancers are early stage and highly curableEuropean Journal Of Cancer, 1998
- Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trialThe Lancet, 1998
- Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised womenThe Lancet, 1998
- Second Cancers After Adjuvant Tamoxifen Therapy for Breast CancerJNCI Journal of the National Cancer Institute, 1996
- Endometrial Cancer following Breast CancerEpidemiology, 1996
- Endometrial müllerian carcinosarcoma after cessation of tamoxifen therapy for breast cancerInternational Journal of Gynecology & Obstetrics, 1995
- Mucinous and Clear Cell Adenocarcinomas of the Endometrium in Patients Receiving Antiestrogens (Tamoxifen) and GestagensInternational Journal of Gynecological Pathology, 1995
- Should clinicians be concerned about the carcinogenic potential of tamoxifen?European Journal Of Cancer, 1994